Adrian Senderowicz

Insider profile

Currently holds positions in Puma Biotechnology Inc and Constellation Pharmaceuticals Inc

Performance

Overall performance
1.6
Performance over holding periods
1.6
30 days 90 days 120 days
Average return -2% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
1 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Puma Biotechnology Inc Aug. 11, 2015 -
Senior Vice President, Chief Medical Officer Constellation Pharmaceuticals Inc July 1, 2017 -
Senior Vice President & Chief Medical Officer Dare Bioscience Inc Aug. 4, 2015 - June 15, 2017
Senior Vice President - Clinical Development and Regulatory Affairs Ignyta Inc May 11, 2015 - Dec. 31, 2015
Chief Medical Officer , Senior Vice President - Clinical Development and Regulatory Affairs Ignyta Inc Aug. 1, 2014 - May 11, 2015
Chief Medical Officer Eledon Pharmaceuticals Inc None -
Adrian Senderowicz's trades of Puma Biotechnology Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Planned sale
Price
132.09
Quantity 10,473 +15.2%
Value US$2,945,769
Transaction date
Proposed sale
Price
297.43
Quantity 72,054
Value US$1,452,800
Transaction date
Planned sale
Price
479.09
Quantity 21,664 -49.8%
Value US$1,300,804
Transaction date
Proposed sale
Price
3.40
Quantity 27,000
Value US$91,767
Transaction date
Planned sale
Price
3.33
Quantity 27,000 -100.0%
Value US$89,818
Transaction date
Proposed sale
Price
3.60
Quantity 27,000
Value US$97,065
Transaction date
Planned sale
Price
3.45
Quantity 27,000 -100.0%
Value US$93,280
Transaction date
Proposed sale
Price
3.46
Quantity 27,000
Value US$93,420
Transaction date
Planned sale
Price
2.63
Quantity 27,858 -50.8%
Value US$73,303
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-15 2026-06-12
PlS Planned sale
10,473 +15.2%
132.09
US$2,945,769 		10,473 +15.2% 132.09 US$2,945,769
2026-06-12 2026-06-12
PrS Proposed sale
72,054
297.43
US$1,452,800 		72,054 297.43 US$1,452,800
2025-06-17 2025-06-13
PlS Planned sale
21,664 -49.8%
479.09
US$1,300,804 		21,664 -49.8% 479.09 US$1,300,804
2025-06-13 2025-06-13
PrS Proposed sale
27,000
3.40
US$91,767 		27,000 3.40 US$91,767
2024-06-17 2024-06-13
PlS Planned sale
27,000 -100.0%
3.33
US$89,818 		27,000 -100.0% 3.33 US$89,818
2024-06-13 2024-06-13
PrS Proposed sale
27,000
3.60
US$97,065 		27,000 3.60 US$97,065
2023-06-15 2023-06-13
PlS Planned sale
27,000 -100.0%
3.45
US$93,280 		27,000 -100.0% 3.45 US$93,280
2023-06-13 2023-06-13
PrS Proposed sale
27,000
3.46
US$93,420 		27,000 3.46 US$93,420
2022-06-21 2022-06-16
PlS Planned sale
27,858 -50.8%
2.63
US$73,303 		27,858 -50.8% 2.63 US$73,303
2020-06-15 2020-06-11
S Sale
10,000 -19.6%
9.89
US$98,878 		10,000 -19.6% 9.89 US$98,878
2020-05-13 2020-05-12
PlS Planned sale
9,357 -37.1%
50.18
US$469,488 		9,357 -37.1% 50.18 US$469,488